Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHANE G CHRISTENSEN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Obstetrics

NPI
1861427189
CMS profile
357354
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$967.59

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $967.59 52

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHANE G CHRISTENSEN

NPI 1861427189 · CMS profile ID 357354

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Obstetrics

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861427189?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHANE G CHRISTENSEN, NPI 1861427189, CMS profile ID 357354. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861427189?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SHANE G CHRISTENSEN, NPI 1861427189, CMS profile ID 357354. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861427189?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SHANE G CHRISTENSEN, NPI 1861427189, CMS profile ID 357354, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1861427189?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $967.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $17.7901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048936155 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.6001/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000109287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,739.03 54
PY2020 $388.25 24
PY2021 $588.68 38
PY2022 $716.57 45
PY2023 $967.59 52
PY2024 $725.29 41
PY2025 $642.12 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,915,239.93 252
PY2024 Recipient $500.00 1
PY2024 Principal investigator $3,165,155.05 347
PY2023 Principal investigator $4,144,892.73 1,305
PY2022 Principal investigator $4,446,303.78 468
PY2021 Principal investigator $6,045,249.00 446
PY2020 Recipient $10,793.30 4
PY2020 Principal investigator $2,860,763.62 257
PY2019 Recipient $1,130.25 1
PY2019 Principal investigator $2,073,996.74 289

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

252 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532931
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine No dispute reported 06/30/2026 1202532933
Principal investigator 1 Merck Sharp & Dohme LLC $63,210.67 12/31/2025 Non-covered Recipient Entity
J Lewis Research Inc,Foothill Family Clinic South
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937310
Principal investigator 1 PFIZER INC. $14,434.20 12/31/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228748720
Principal investigator 1 PFIZER INC. $4,050.00 12/23/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228747130
Principal investigator 1 ModernaTX, Inc. $320.00 12/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987194
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001133
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001139
Principal investigator 1 ModernaTX, Inc. $500.00 12/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001145
Principal investigator 1 ModernaTX, Inc. $2,500.00 12/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001169
Principal investigator 1 PFIZER INC. $34,874.82 12/17/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228714691
Principal investigator 1 PFIZER INC. $18,225.00 12/17/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228722898
Principal investigator 1 PFIZER INC. $15,550.00 12/12/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228750804
Principal investigator 1 PFIZER INC. $59,134.85 12/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228733378
Principal investigator 1 PFIZER INC. $1,170.00 12/08/2025 Non-covered Recipient Entity
Foothill Family Clinic South J Lewis Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728453
Principal investigator 1 PFIZER INC. $454.50 12/08/2025 Non-covered Recipient Entity
Foothill Family Clinic South J Lewis Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728995
Principal investigator 1 PFIZER INC. $303.00 12/08/2025 Non-covered Recipient Entity
Foothill Family Clinic South J Lewis Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728999
Principal investigator 1 ModernaTX, Inc. $3,522.94 12/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987250
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228719875
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725396
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725544
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725546
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725906
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726258
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726328
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726330
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732319
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736326
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736329
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736423
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736427
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736476
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736591
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736636
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736677
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228738677
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228739023
Principal investigator 1 PFIZER INC. $426.60 12/05/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228739234
Principal investigator 1 Merck Sharp & Dohme LLC $23,202.35 12/03/2025 Non-covered Recipient Entity
J Lewis Research Inc,Foothill Family Clinic South
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937308
Principal investigator 1 ModernaTX, Inc. $400.00 12/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987268
Principal investigator 1 PFIZER INC. $587.50 12/02/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228718023
Principal investigator 1 PFIZER INC. $15,300.00 11/27/2025 Non-covered Recipient Entity
JLewis Research Inc
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228723072
Principal investigator 1 PFIZER INC. $31,387.50 11/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228738902
Principal investigator 1 ABBVIE INC. $1,500.00 11/26/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202525570
Principal investigator 1 PFIZER INC. $14,360.22 11/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228714693
Principal investigator 1 PFIZER INC. $4,168.00 11/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228738920
Principal investigator 1 ModernaTX, Inc. $5,469.66 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001125
Principal investigator 1 ModernaTX, Inc. $17,569.44 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001127
Principal investigator 1 ModernaTX, Inc. $6,757.52 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001135
Principal investigator 1 ModernaTX, Inc. $5,299.83 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001137
Principal investigator 1 ModernaTX, Inc. $4,022.64 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001143
Principal investigator 1 ModernaTX, Inc. $3,454.00 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001147
Principal investigator 1 ModernaTX, Inc. $792.12 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001157
Principal investigator 1 ModernaTX, Inc. $739.50 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001161
Principal investigator 1 ModernaTX, Inc. $30,149.28 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001163
Principal investigator 1 ModernaTX, Inc. $3,124.80 11/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001165
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719905
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724952
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725566
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725632
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725634
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228726164
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733663
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228736480
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228736957
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228737425
Principal investigator 1 ModernaTX, Inc. $6,534.67 11/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987198
Principal investigator 1 PFIZER INC. $2,025.00 11/20/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228724556
Principal investigator 1 PFIZER INC. $180.80 11/18/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228720303
Principal investigator 1 PFIZER INC. $180.80 11/18/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228727955
Principal investigator 1 PFIZER INC. $265.20 11/18/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228728067
Principal investigator 1 PFIZER INC. $265.20 11/18/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228729466
Principal investigator 1 PFIZER INC. $7,087.50 11/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728119
Principal investigator 1 PFIZER INC. $105.30 11/14/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228727985
Principal investigator 1 PFIZER INC. $148.60 11/14/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728427
Principal investigator 1 PFIZER INC. $11.70 11/14/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728991
Principal investigator 1 PFIZER INC. $22,645.98 11/13/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228714883
Principal investigator 1 ModernaTX, Inc. $1,100.37 11/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987234
Principal investigator 1 PFIZER INC. $272.70 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc South
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228723208
Principal investigator 1 PFIZER INC. $272.70 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc South
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228727953
Principal investigator 1 PFIZER INC. $221.58 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc South
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228727987
Principal investigator 1 PFIZER INC. $221.58 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc South
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228728353
Principal investigator 1 PFIZER INC. $7,087.50 11/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728575
Principal investigator 1 ABBVIE INC. $25.82 11/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522419
Principal investigator 1 PFIZER INC. $14,050.00 11/04/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF VACCINE CANDIDATES AGAINST RESPIRATORY SYNCYTIAL VIRUS HUMAN METAPNEUMOVIRUS ANDOR HUMAN PARAINFLUENZA VIRUS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228738393
Principal investigator 1 PFIZER INC. $148.60 10/31/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728077
Principal investigator 1 PFIZER INC. $117.00 10/31/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728455
Principal investigator 1 PFIZER INC. $1,012.50 10/30/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228755262
Principal investigator 1 ModernaTX, Inc. $840.00 10/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987200
Principal investigator 1 ModernaTX, Inc. $200.00 10/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987208
Principal investigator 1 ModernaTX, Inc. $748.80 10/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987210
Principal investigator 1 PFIZER INC. $117.00 10/27/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728075
Principal investigator 1 PFIZER INC. $148.60 10/27/2025 Non-covered Recipient Entity
J Lewis ResFoothill ClncS
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728137
Principal investigator 1 PFIZER INC. $2,465.00 10/23/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228741069
Principal investigator 1 ModernaTX, Inc. $4,729.73 10/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987266
Principal investigator 1 PFIZER INC. $1,279.80 10/22/2025 Non-covered Recipient Entity
J Lewis Research
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228725542
Principal investigator 1 PFIZER INC. $101,674.53 10/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228741271
Principal investigator 1 PFIZER INC. $147.72 10/20/2025 Non-covered Recipient Entity
JlewisFoothill Clinic South
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228714276
Principal investigator 1 PFIZER INC. $181.80 10/20/2025 Non-covered Recipient Entity
JlewisFoothill Clinic South
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228715439
Principal investigator 1 PFIZER INC. $40,500.00 10/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228741646
Principal investigator 1 PFIZER INC. $14,134.00 10/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228741738
Principal investigator 1 ABBVIE INC. $6,097.90 10/09/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515595
Principal investigator 1 PFIZER INC. $1,563.30 09/30/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228743649
Principal investigator 1 PFIZER INC. $25,312.50 09/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228768744
Principal investigator 1 PFIZER INC. $757.50 09/24/2025 Non-covered Recipient Entity
JlewisFoothill Clinic South
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228740018
Principal investigator 1 PFIZER INC. $615.50 09/24/2025 Non-covered Recipient Entity
JlewisFoothill Clinic South
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228740022
Principal investigator 1 PFIZER INC. $13,512.50 09/24/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228753037
Principal investigator 1 PFIZER INC. $4,266.00 09/23/2025 Non-covered Recipient Entity
J Lewis Research South
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228715441
Principal investigator 1 ModernaTX, Inc. $12,056.85 09/19/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987218
Principal investigator 1 PFIZER INC. $14,175.00 09/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228758358
Principal investigator 1 ModernaTX, Inc. $160.00 09/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987242
Principal investigator 1 ModernaTX, Inc. $118.56 08/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012204
Principal investigator 1 ModernaTX, Inc. $3,975.75 08/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987202
Principal investigator 1 ModernaTX, Inc. $13,586.32 08/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987214
Principal investigator 1 ModernaTX, Inc. $12,700.80 08/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987224
Principal investigator 1 PFIZER INC. $2,025.00 08/21/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228768165
Principal investigator 1 PFIZER INC. $1,012.50 08/05/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228784988
Principal investigator 1 PFIZER INC. $48,900.00 08/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228759917
Principal investigator 1 PFIZER INC. $13,092.64 07/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228772034
Principal investigator 1 ModernaTX, Inc. $10,647.11 07/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987256
Principal investigator 1 ModernaTX, Inc. $550.00 07/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987232
Principal investigator 1 ModernaTX, Inc. $250.00 07/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987246
Principal investigator 1 ModernaTX, Inc. $110.00 07/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001155
Principal investigator 1 PFIZER INC. $25,425.00 07/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228782328
Principal investigator 1 ModernaTX, Inc. $140.40 07/09/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012218
Principal investigator 1 ModernaTX, Inc. $2,545.14 07/09/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012226
Principal investigator 1 ModernaTX, Inc. $1,992.00 07/09/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012236
Principal investigator 1 PFIZER INC. $91,912.86 07/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771282
Principal investigator 1 ABBVIE INC. $1,918.80 07/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496639
Principal investigator 1 ModernaTX, Inc. $3,009.56 07/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987184
Principal investigator 1 PFIZER INC. $5,085.45 07/02/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228720581
Principal investigator 1 PFIZER INC. $3,559.95 06/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228774717
Principal investigator 1 ModernaTX, Inc. $80.00 06/25/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987258
Principal investigator 1 PFIZER INC. $30,348.00 06/21/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228776124
Principal investigator 1 ModernaTX, Inc. $7,159.05 06/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987196
Principal investigator 1 ModernaTX, Inc. $448.30 06/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012192
Principal investigator 1 PFIZER INC. $1,977.75 06/14/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228792187
Principal investigator 1 ModernaTX, Inc. $218.40 06/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012190
Principal investigator 1 ModernaTX, Inc. $1,248.00 06/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012208
Principal investigator 1 ModernaTX, Inc. $46.80 06/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012220
Principal investigator 1 PFIZER INC. $90,271.18 06/10/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228776139
Principal investigator 1 ModernaTX, Inc. $7,209.65 06/04/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987204
Principal investigator 1 ABBVIE INC. $24.55 06/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489533
Principal investigator 1 ABBVIE INC. $677.54 06/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489773
Principal investigator 1 PFIZER INC. $13,636.35 05/30/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723946
Principal investigator 1 ModernaTX, Inc. $54,244.30 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012196
Principal investigator 1 ModernaTX, Inc. $3,107.26 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012206
Principal investigator 1 ModernaTX, Inc. $11,480.56 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012228
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707832
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228759647
Principal investigator 1 PFIZER INC. $150.00 05/23/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228766077
Principal investigator 1 ModernaTX, Inc. $12,741.98 05/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987260
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707449
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707451
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761389
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769658
Principal investigator 1 PFIZER INC. $45,121.06 05/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228772822
Principal investigator 1 ModernaTX, Inc. $480.00 05/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987254
Principal investigator 1 PFIZER INC. $3,204.06 05/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228772462
Principal investigator 1 ABBVIE INC. $3,387.72 05/07/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483047
Principal investigator 1 ModernaTX, Inc. $500.00 05/07/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987190
Principal investigator 1 PFIZER INC. $492.00 05/07/2025 Non-covered Recipient Entity
JLewis Foothill Family Clin S
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228768330
Principal investigator 1 PFIZER INC. $564.40 05/07/2025 Non-covered Recipient Entity
JLewis Foothill Family Clin S
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771082
Principal investigator 1 ModernaTX, Inc. $6,295.25 05/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987188
Principal investigator 1 ABBVIE INC. $73.65 05/01/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202480765
Principal investigator 1 PFIZER INC. $27,006.83 05/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228782938
Principal investigator 1 ModernaTX, Inc. $36,760.60 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012194
Principal investigator 1 ModernaTX, Inc. $20,451.60 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012216
Principal investigator 1 ModernaTX, Inc. $17,089.93 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012224
Principal investigator 1 ModernaTX, Inc. $150.00 04/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001129
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001141
Principal investigator 1 ModernaTX, Inc. $625.00 04/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001167
Principal investigator 1 ModernaTX, Inc. $200.00 04/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987230
Principal investigator 1 ModernaTX, Inc. $4,089.82 04/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987236
Principal investigator 1 PFIZER INC. $3,184.20 04/16/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228795556
Principal investigator 1 PFIZER INC. $521.10 04/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228797867
Principal investigator 1 ABBVIE INC. $36.83 04/08/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202474838
Principal investigator 1 ABBVIE INC. $5,420.36 04/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202468980
Principal investigator 1 ModernaTX, Inc. $21,695.13 04/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987248
Principal investigator 1 ModernaTX, Inc. $280.00 04/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987264
Principal investigator 1 PFIZER INC. $395.55 04/02/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723868
Principal investigator 1 PFIZER INC. $34,373.20 03/28/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228787329
Principal investigator 1 PFIZER INC. $1,227.15 03/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228779859
Principal investigator 1 ModernaTX, Inc. $13,982.67 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012222
Principal investigator 1 ModernaTX, Inc. $2,241.50 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012230
Principal investigator 1 ModernaTX, Inc. $17,981.60 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012238
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707662
Principal investigator 1 PFIZER INC. $189.80 03/23/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761384
Principal investigator 1 PFIZER INC. $7,745.50 03/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228783261
Principal investigator 1 ModernaTX, Inc. $14,113.58 03/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987240
Principal investigator 1 ModernaTX, Inc. $312.00 03/20/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012214
Principal investigator 1 PFIZER INC. $90,242.12 03/20/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228722488
Principal investigator 1 ABBVIE INC. $24.55 03/19/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202464354
Principal investigator 1 ModernaTX, Inc. $1,620.00 03/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987252
Principal investigator 1 ModernaTX, Inc. $400.00 03/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987272
Principal investigator 1 PFIZER INC. $2,969.46 03/12/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228780980
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707750
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228719559
Principal investigator 1 ABBVIE INC. $1,735.00 03/06/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202458180
Principal investigator 1 PFIZER INC. $14,600.00 03/04/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228794961
Principal investigator 1 ModernaTX, Inc. $34,967.40 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012186
Principal investigator 1 ModernaTX, Inc. $20,688.72 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012188
Principal investigator 1 ModernaTX, Inc. $24,858.08 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012198
Principal investigator 1 ModernaTX, Inc. $748.80 02/26/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987186
Principal investigator 1 ModernaTX, Inc. $150.00 02/26/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987212
Principal investigator 1 ModernaTX, Inc. $200.00 02/26/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987228
Principal investigator 1 ModernaTX, Inc. $28,413.45 02/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987274
Principal investigator 1 ModernaTX, Inc. $165.00 02/20/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001159
Principal investigator 1 PFIZER INC. $48.60 02/19/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228751235
Principal investigator 1 ABBVIE INC. $5,800.00 02/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202452287
Principal investigator 1 PFIZER INC. $158.50 02/17/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707836
Principal investigator 1 PFIZER INC. $158.50 02/17/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769653
Principal investigator 1 ModernaTX, Inc. $679.05 02/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987216
Principal investigator 1 ModernaTX, Inc. $3,645.00 02/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987238
Principal investigator 1 PFIZER INC. $28,005.48 02/12/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228757129
Principal investigator 1 ModernaTX, Inc. $3,276.00 02/10/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012210
Principal investigator 1 ModernaTX, Inc. $46.80 02/10/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012234
Principal investigator 1 ModernaTX, Inc. $5,938.66 02/10/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012242
Principal investigator 1 PFIZER INC. $4,115.00 02/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769537
Principal investigator 1 ModernaTX, Inc. $4,455.00 02/07/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987270
Principal investigator 1 ModernaTX, Inc. $1,000.00 02/06/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001131
Principal investigator 1 ABBVIE INC. $2,215.00 02/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202444990
Principal investigator 1 ModernaTX, Inc. $125.00 02/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987222
Principal investigator 1 ModernaTX, Inc. $1,400.00 02/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987244
Principal investigator 1 ModernaTX, Inc. $15,069.60 02/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012202
Principal investigator 1 PFIZER INC. $2,350.00 02/04/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707834
Principal investigator 1 ModernaTX, Inc. $200.00 02/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987220
Principal investigator 1 PFIZER INC. $726.10 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707660
Principal investigator 1 PFIZER INC. $317.00 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707752
Principal investigator 1 PFIZER INC. $726.10 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762152
Principal investigator 1 PFIZER INC. $317.00 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769122
Principal investigator 1 PFIZER INC. $837.08 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228774915
Principal investigator 1 PFIZER INC. $981.24 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic South
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228786560
Principal investigator 1 ModernaTX, Inc. $400.00 01/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987206
Principal investigator 1 ModernaTX, Inc. $2,964.00 01/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252987226
Principal investigator 1 ModernaTX, Inc. $28,592.45 01/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001149
Principal investigator 1 PFIZER INC. $1,914.84 01/29/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801731
Principal investigator 1 ModernaTX, Inc. $15,690.50 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012200
Principal investigator 1 ModernaTX, Inc. $13,982.67 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012212
Principal investigator 1 ModernaTX, Inc. $11,282.96 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012232
Principal investigator 1 ModernaTX, Inc. $1,067.04 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012240
Principal investigator 1 PFIZER INC. $4,743.90 01/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798310
Principal investigator 1 PFIZER INC. $15,488.50 01/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228802041
Principal investigator 1 ModernaTX, Inc. $11,010.26 01/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987192
Principal investigator 1 ModernaTX, Inc. $606.83 01/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001151
Principal investigator 1 ModernaTX, Inc. $64.50 01/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001153
Principal investigator 1 PFIZER INC. $2,374.92 01/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798348
Principal investigator 1 ModernaTX, Inc. $160.00 01/15/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252987262
Principal investigator 1 PFIZER INC. $700.00 01/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228723474
Principal investigator 1 PFIZER INC. $2,393.55 01/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800100
Principal investigator 1 PFIZER INC. $478.71 01/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799984
Principal investigator 1 PFIZER INC. $10,803.06 01/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801645